Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma

References

• Guinee V F, Giacco G G, Durand M, van den Blink J W, Gustavsson A, Zewuster R, et al. The prognosis of Hodgkin's disease in older adults. J Clin Oncol 1991; 9: 947–953
   PubMed Web of Science ®Google Scholar
• Diaz-Pavon J R, Cabanillas F, Majiis A, Hagemeister F B. Outcome of Hodgkin's disease in elderly patients. Hematol Oncol 1995; 13: 19–27
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease. N Eng J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• van Spronsen D J, Janssen-Heijnen M L, Lemmens V E, Peters W G, Coebergh J W. Independent prognostic effect of co-morbidity in lymphoma patients: Results of the population-based Eindhoven Cancer Registry. Eur J Cancer 2005; 41: 1051–1057
   PubMed Web of Science ®Google Scholar
• Erdkamp F L, Breed W P, Bosch L J, Wijnen J T, Blijham G B. Hodgkin's disease in the elderly. A registry-based analysis. Cancer 1992; 70: 830–834
   PubMed Web of Science ®Google Scholar
• Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Duhmke E, , for German Hodgkin's Study Group, et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052–5060
   PubMed Web of Science ®Google Scholar
• Stark G L, Wood K M, Jack F, Angus B, Proctor S J, Taylor P R, on behalf of the Northern Region Lymphoma Group. Hodgkin's disease in the elderly: A population-based study. B J Haematol 2002; 119: 432–440
   PubMed Web of Science ®Google Scholar
• Keegan T H, Glaser S L, Clarke C A, Gulley M L, Craig F E, Digiuseppe J A, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population based study. J Clin Oncol 2005; 23: 7604–7613
   PubMed Web of Science ®Google Scholar
• Jarret R F, Stark G L, White J, Angus B, Alexander F E, Krajewski A S, , for the Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma. Blood 2005; 106: 2444–2451
   PubMed Web of Science ®Google Scholar
• Specht L, Nissen N I. Hodgkin's disease and age. Eur J Haematol 1989; 43: 127–135
   PubMed Web of Science ®Google Scholar
• Enblad G, Glimerius B, Sundstrom C. Treatment outcome in Hodgkin's disease in patients above the age of 60: A population based study. Ann Oncol 1991; 297–302
   PubMed Web of Science ®Google Scholar
• Levis A, Anselmo A P, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, , on behalf of the Intergruppo Italiano Linfomi (IIL) VEPEMB in elderly Hodgkin's lymphoma patients, et al. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004; 15: 123–128
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper M R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Eng J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Proctor S J, White J, Jones G L. An international approach to the treatment of Hodgkin's disease in the elderly: Launch of the SHIELD study program. Eur J Haematol Suppl 2005; 66: 63–67
   PubMedGoogle Scholar
• Bosi A, Ponticelli P, Casini C, Messori A, Bellesi G, Biti G, et al. Clinical data and therapeutic approach in elderly patients with Hodgkin's disease. Hematologica 1989; 74: 463–473
   PubMed Web of Science ®Google Scholar
• Proctor S J, Rueffer J U, Angus B, Breuer K, Flechter H, Jarret R, et al. Hodgkin's disease in the elderly: Current status and future directions. Ann Oncol 2002; 13: 133–137
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Burton C, Linch D, Hoskin P, Milligan D, Dyer M J, Hancock B, et al. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer 2006; 94: 806–813
   PubMed Web of Science ®Google Scholar
• Enblad G, Gustavsson A, Sundstrom C, Glimerius B, Swedish Lymphoma Study Group. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. Acta Oncol 2002; 41: 659–667
   PubMed Web of Science ®Google Scholar
• Ballova V, Ruffer J U, Haverkamp H, Pfister B, Muller-Hermelink H K, Dumpke E, et al. A prospective randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005; 16: 124–131
   PubMed Web of Science ®Google Scholar
• Macpherson N, Klasa R J, Gascoyne R, O'Reilly S E, Voss N, Connors J M. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): A phase II study. Leuk Lymphoma 2002; 43: 1395–1402
   PubMed Web of Science ®Google Scholar
• Martin W G, Ristow K M, Habermann T M, Clgan J P, Witzig T, Ansell S M. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005; 30: 7614–7620
   Web of Science ®Google Scholar
• Canellos G P, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the Adriamycn + bleomycin + vinblastine + dacarbacine regimen?. J Clin Oncol 2004; 22: 1532–1533
   PubMed Web of Science ®Google Scholar
• Levis A, Depaoli L, Bertini M, Botto B, Cirvegna G, Freilone R, et al. Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin's disease patients. Haematologica 1996; 81: 450–456
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Magagnali M, Bendandi M, Barbieri E, Galuppi A, Gherlinzoni F, et al. Efficacy of VBM regimen in the treatment of elderly patients with Hodgkin's disease. Haematologica 2000; 85: 729–732
   PubMed Web of Science ®Google Scholar
• Radford J A, Crowther D, Rohatiner A Z, Ryder W D, Gupta R K, Oza A, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13: 2379–2385
   PubMed Web of Science ®Google Scholar
• Weekes C D, Vose J M, Lynch J C, Weisenburger D D, Bierman P J, Greiener T, , for the Nebraska Lymphoma Study Group, et al. Hodgkin's disease in the elderly: Improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 2002; 20: 1087–1093
   PubMed Web of Science ®Google Scholar
• Van Spronsen D J, Janssen-Heijnen M IG, Breed W P, Coebergh J WW. Prevalence of co-morbidity and its relationship to treatment outcome among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993 – 1996. Ann Hematol 1999; 78: 315–319
   PubMed Web of Science ®Google Scholar
• Roy P, Vaughan Hudson G, Vaughan Hudson B, Esteve J, Swerdlow A. Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based registries. Eur J Cancer 2000; 36: 384–389
   PubMed Web of Science ®Google Scholar
• Smith T J, Khatcheressian J, Lyman G H, Ozer H, Armitage J O, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guide. J Clin Oncol 2006; 24: 3187–3206
   PubMed Web of Science ®Google Scholar